Sunesis second-quarter revenues up at $6.7 million, enrollment in several clinical trials continues

By Lisa Kerner

Charlotte, N.C., Aug. 10 - Sunesis Pharmaceuticals, Inc.'s second-quarter total revenues were up at $6.7 million from $4.8 million for the prior-year period.

The company reported a net loss for the quarter ended June 30 of $4.5 million, or $0.15 per share, compared with a net loss of $12 million, or $8.55 per share, for the second-quarter 2005.

As of June 30, cash, cash equivalents and marketable securities totaled $79.1 million, down by $3.2 million compared to March 31.

For the six-month period ended June 30, Sunesis' total revenues rose to $9.8 million from $8.7 million for the prior-year period.

Sunesis had net loss of $13.4 million, or $0.52 per share, for the first half of 2006, an improvement from the net loss of $16.5 million, or $11.88 per share, reported fro the first half of 2005.

The company said it is continuing to enroll patients in two phase 2 clinical trials of SNS-595 in non-small cell lung cancer and small cell lung cancer, a phase 1 trial of SNS-595 in acute leukemias and a phase 1/ 2 trial of SNS-032 in solid tumors.

In addition, Sunesis remains on track to file an Investigational New Drug application for SNS-314, an Aurora kinase inhibitor, by the end of 2006.

Sunesis is a clinical-stage biopharmaceutical company based in South San Francisco, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.